antibodybas
therapeut
modal
shown
clinic
success
treatment
mani
diseas
recent
year
tremend
effort
made
engin
bispecif
multispecif
antibodi
combin
two
function
antigenrecogn
element
singl
construct
novel
antibodi
antibodybas
fusion
protein
could
particularli
benefici
treatment
viral
infect
typic
requir
potent
multifunct
therapeut
prevent
frequent
incid
viral
escap
mutant
instanc
previous
engin
bispecif
multival
fusion
protein
incorpor
neutral
antibodi
engin
singledomain
singl
antibodylik
molecul
found
abl
neutral
test
isol
mediat
potent
antibodydepend
cellular
cytotox
adcc
cell
effect
suppress
shiv
infect
human
mice
chronic
infect
macaqu
notabl
addit
antibodybas
therapeut
polypeptidesbas
fusion
inhibitor
repres
anoth
type
effect
antivir
could
inhibit
entri
virus
inhibit
virusmedi
cellcel
fusion
howev
due
vast
differ
activ
bioavail
biophys
properti
polypeptid
monoclon
antibodi
report
case
antibodypeptid
bispecif
fusion
protein
abl
effect
neutral
inhibit
cellcel
fusion
mediat
virus
middl
east
respiratori
syndrom
coronaviru
merscov
novel
coronaviru
first
isol
septemb
patient
saudi
arabia
caus
sarslik
symptom
includ
fever
cough
short
breath
lead
respiratori
renal
failur
bat
natur
reservoir
merscov
predominantli
transmit
via
dromedari
camel
human
end
may
countri
report
laboratoryconfirm
case
merscov
infect
least
relat
death
sinc
septemb
http
wwwwhointemergenciesmerscoven
effect
therapeut
vaccin
urgent
need
consid
possibl
evolut
pandem
potenti
merscov
like
sarscov
merscov
envelop
viru
use
spike
protein
enter
target
cell
protein
cleav
two
subunit
wherebi
subunit
bind
cellular
receptor
subunit
mediat
membran
fusion
therefor
subunit
could
target
develop
prophylact
therapeut
agent
merscov
infect
previou
studi
screen
larg
phagedisplay
antibodi
fab
librari
identifi
panel
human
neutral
monoclon
antibodi
mab
target
receptor
bind
domain
rbd
merscov
protein
subunit
among
antibodi
mab
show
potent
viru
neutral
activ
low
nanomolar
concentr
structur
studi
indic
bind
epitop
merscov
almost
complet
overlap
viral
receptorbind
site
reveal
mechan
high
neutral
potenc
meanwhil
fusion
inhibitori
peptid
deriv
heptad
repeat
domain
merscov
protein
subunit
inhibit
format
six
helix
bundl
requir
fusion
viru
target
cell
two
peptid
report
interact
heptad
repeat
domain
protein
subunit
form
complex
block
viral
fusion
replic
recent
found
combin
antibodi
peptid
exhibit
potent
synerg
inhibit
merscov
proteinmedi
cellcel
fusion
pseudoviru
infect
howev
peptid
mix
antibodi
molar
concentr
ratio
synerg
effect
observ
mix
peptid
antibodi
ratio
probabl
due
signific
differ
peptid
antibodi
bioactiv
biophys
properti
four
construct
scfv
scfvpep
diabodypep
gener
scfv
gener
link
variabl
region
heavi
variabl
region
light
chain
amino
acid
linker
fusion
protein
scfvpep
prepar
link
scfv
merscovderiv
peptid
ltqinttlldltyemlslqqvvkalnesyidlkel
use
anoth
linker
spacer
fusion
protein
diabodypep
gener
replac
linker
vh
vl
scfvpep
amino
acid
gggg
linker
two
vh
vl
pair
togeth
form
dimer
diabodi
also
gener
fuse
peptid
domain
code
fragment
synthes
genewiz
biotech
co
insert
two
sfii
restrict
site
vector
flagtag
dykddddk
ctermini
sequenc
construct
verifi
direct
dna
sequenc
four
construct
express
solubl
protein
e
coli
purifi
ninta
column
briefli
express
vector
transform
e
coli
strain
compet
cell
singl
fresh
coloni
inocul
ml
medium
contain
ampicillin
incub
rpm
overnight
incub
cultur
transfer
ml
fresh
medium
ampicillin
largescal
protein
product
h
growth
mm
iptg
appli
induc
protein
overexpress
cell
grown
overnight
harvest
centrifug
protein
fragment
harvest
bacteri
cell
pellet
precipit
resuspend
ml
pb
nacl
ml
polymyxin
b
ad
lyse
bacteria
sampl
rotat
min
room
temperatur
rpm
cultur
centrifug
rpm
min
supernat
collect
load
onto
ninta
superflow
qiagen
redwood
citi
ca
usa
impur
remov
target
protein
elut
elut
buffer
mm
imidazol
pb
protein
resolv
sdspage
puriti
estim
protein
puriti
confirm
size
exclus
chromatographi
use
fplc
akta
system
ge
healthcar
chicago
il
usa
superdex
gl
column
ge
healthcar
protein
concentr
measur
spectrophotometr
nanovu
ge
healthcar
experi
perform
use
proteon
system
biorad
hercul
ca
usa
measur
bind
kinet
scfv
scfvpep
diabodypep
merscov
protein
amino
acid
protein
immobil
proteon
glm
biosensor
chip
use
standard
amin
coupl
chemistri
nm
mm
sodium
acet
buffer
ph
reson
unit
immobil
surfac
sensor
chip
activ
mm
aminopropylcarbodiimid
hydrochlorid
mm
nhydroxysulfosuccinimid
scfv
scfvpep
diabodypep
prepar
pb
ph
contain
pbst
inject
dilut
nm
dissoci
phase
follow
chip
surfac
regener
inject
mm
glycin
hcl
data
analyz
use
proteon
manag
softwar
fit
interact
model
merscov
neutral
assay
perform
previous
describ
briefli
cell
dish
transient
cotransfect
plasmid
plasmid
encod
envdefect
luciferaseexpress
h
posttransfect
produc
pseudoviru
harvest
supernat
filter
steril
membran
merscov
pseudoviru
incub
four
inhibitor
min
pseudoviru
inhibitor
ad
cell
preplat
well
tissu
cultur
plate
h
h
fresh
medium
ad
plate
incub
anoth
h
cell
lyse
lysi
reagent
promega
madison
wi
usa
lysat
transfer
costar
flatbottom
luminomet
plate
corn
corn
ny
usa
luciferas
substrat
ad
read
record
ultra
micropl
reader
tecan
switzerland
compar
inhibitori
effect
fusion
protein
cellcel
fusion
assay
perform
merscov
protein
express
cell
surfac
mediat
cell
fusion
neighbor
cell
first
cell
transient
transfect
paairesmersegfp
effector
cell
encod
merscov
protein
paairesegfp
neg
control
cell
cultur
dmem
contain
fb
h
preplat
cell
target
cell
express
merscov
receptor
cultur
well
plate
h
addit
cell
dilut
scfv
scfvpep
diabodypep
mixtur
cell
target
cell
cultur
h
fuse
unfus
cell
visual
invert
fluoresc
microscop
nikon
eclips
nikon
tokyo
japan
gener
bispecif
antibodypeptid
inhibitor
merscov
peptid
fuse
scfv
use
flexibl
linker
furthermor
dimer
format
name
diabodypep
also
gener
replac
linker
variabl
region
heavi
vh
variabl
region
light
vl
scfv
amino
acid
gggg
linker
shorter
linker
result
pair
vh
vl
two
differ
chain
thu
format
dimer
diabodi
two
vh
vl
dimer
peptideonli
control
name
also
gener
link
peptid
domain
flexibl
linker
fusion
protein
possess
two
peptid
compar
molecular
weight
compar
construct
figur
four
protein
scfv
scfvpep
diabodypep
solubl
express
e
coli
cell
high
effici
purifi
protein
obtain
yield
mgl
bacteri
cultur
diabodypep
migrat
monom
denatur
condit
sdspage
thu
display
similar
molecular
weight
kda
scfv
scfvpep
figur
protein
monomer
demonstr
size
exclus
chromatographi
data
shown
measur
bind
kinet
fusion
protein
merscov
protein
surfac
plasmon
reson
spr
assay
perform
use
proteon
system
spr
biosensor
instrument
figur
previous
demonstr
bound
specif
merscov
protein
unrel
protein
shown
tabl
three
fusion
protein
scfv
scfvpep
diabodypep
exhibit
potent
bind
protein
similar
bind
pattern
equilibrium
dissoci
constant
kd
scfv
protein
nm
onrat
kon
offrat
koff
diabodypep
display
similar
bind
kinet
scfv
kon
koff
kd
nm
scfvpep
slightli
potent
bind
affin
kd
nm
slower
dissoci
rate
constant
koff
compar
two
fusion
protein
contrast
display
much
lower
affin
compar
antibodi
fusion
protein
kd
next
measur
neutral
activ
scfv
scfvpep
diabodypep
grade
concentr
pseudotyp
merscov
infect
shown
figur
scfvpep
diabodypep
exhibit
potent
neutral
activ
among
scfvpep
exhibit
potent
neutral
capabl
inhibitori
concentr
nm
although
display
compar
diabodypep
nm
scfv
nm
interestingli
diabodypep
inhibit
infect
potent
scfv
low
protein
concentr
nm
previou
studi
display
except
neutral
pseudotyp
merscov
infect
nm
control
fusion
protein
could
inhibit
infect
use
wellestablish
merscov
proteinmedi
cellcel
fusion
assay
determin
whether
fusion
protein
abil
inhibit
merscov
fusion
target
cell
assay
cell
express
merscov
protein
egfp
use
effector
cell
cell
express
receptor
use
target
cell
show
appreci
activ
concentr
nm
consist
previou
report
peptid
signific
inhibitori
effect
concentr
lower
nm
notabl
found
diabodypep
abl
block
fusion
cell
cell
concentr
low
nm
figur
calcul
diabodypep
nm
shown
figur
diabodypep
significantli
potent
scfv
inhibit
cellcel
fusion
scfvpep
also
show
evid
potent
inhibitori
activ
scfv
low
concentr
slightli
lower
scfvpep
nm
scfv
nm
result
indic
antibodypeptid
bispecif
fusion
protein
especi
diabodypep
potenti
develop
potent
merscov
inhibitor
could
neutral
merscov
infect
also
inhibit
merscov
proteinmedi
cellcel
fusion
monoclon
antibodi
repres
one
promis
immunotherapeut
agent
treatment
cancer
infecti
diseas
previous
use
rbd
merscov
protein
screen
nonimmun
phagedisplay
fab
librari
identifi
highli
potent
human
neutral
mab
panel
mab
merscov
jiang
et
al
also
use
merscov
rbd
screen
nonimmun
yeastdisplay
scfv
librari
identifi
two
potent
merscov
neutral
mab
tang
et
al
use
fulllength
protein
screen
nonimmun
phagedisplay
scfv
librari
identifi
potent
merscov
neutral
mab
report
mab
inhibit
bind
viru
cellular
report
recogn
differ
epitop
rbd
thu
potenti
develop
antimerscov
therapeut
howev
engin
still
need
address
concern
use
mab
clinic
eg
high
product
cost
etc
studi
gener
two
bispecif
antimerscov
fusion
protein
scfvpep
diabodypep
compar
antibodi
peptid
inhibitor
block
one
site
spike
protein
bispecif
inhibitor
show
greater
potenc
scfvpep
show
highest
bind
affin
merscov
protein
well
potent
neutral
activ
diabodypep
potent
block
merscov
smediat
cellcel
fusion
result
confirm
improv
potenc
bispecif
antibodypeptid
inhibitor
compar
antibodi
peptid
alon
interfer
viral
attach
receptor
human
cell
peptid
inhibit
format
fusion
core
thu
interrupt
viral
fusion
target
cell
membran
probabl
antibodypeptid
fusion
protein
compos
antivir
compon
link
flexibl
linker
act
step
viral
infect
interestingli
diabodypep
found
potent
block
merscov
smediat
cellcel
fusion
even
concentr
lower
nm
phenomenon
may
attribut
differ
steric
hindranc
fusion
protein
compar
scfvpep
diabodypep
much
larger
twice
molecular
weight
size
thu
inhibit
viral
fusion
target
cell
competit
inhibit
steric
hindranc
lead
much
greater
inhibitori
activ
scfvpep
although
larg
improv
potenc
inhibit
cellcel
fusion
diabodypep
show
evid
increas
neutral
activ
compar
scfv
investig
requir
explor
mechan
dispar
perform
diabodypep
differ
assay
shown
figur
figur
diabodypep
nm
neutral
assay
nm
cellcel
fusion
assay
importantli
diabodypep
much
potent
scfv
concentr
higher
nm
cellcel
fusion
assay
concentr
fusion
protein
result
high
percentag
inhibit
neutral
assay
therefor
may
explain
littl
differ
among
differ
group
fusion
protein
could
easili
produc
e
coli
larg
amount
low
product
cost
size
larger
scfv
peptid
suggest
would
possess
longer
vivo
halflif
still
halflif
would
shorter
fullsiz
igg
due
lack
fc
region
therefor
prophylact
therapeut
efficaci
merscov
assess
care
use
differ
approach
dose
vivo
howev
rbd
merscov
specif
target
human
small
anim
model
suscept
merscov
infect
pose
signific
barrier
develop
antimerscov
inhibitor
fortun
research
construct
sever
anim
model
recent
simul
morbid
mortal
human
infect
nonhuman
primat
nhp
model
human
mous
model
consid
ideal
candid
latter
promis
util
follow
studi
conclus
studi
indic
bispecif
inhibitor
increas
efficaci
merscov
compar
neutral
antibodi
polypeptid
alon
inhibitor
advantag
multipl
biolog
potenti
develop
effect
prophylact
therapeut
agent
may
find
wide
applic
treat
viral
diseas
